Please provide your email address to receive an email when new articles are posted on . More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks.

It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%. 1 Left untreated, MASH ...

2 MISSISSAUGA, ON, May 2, 2025 /CNW/ - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

How Does Semaglutide Work for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic. Wegovy. Rybelsus. What do these medications have in common? They all contain ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Ebn Sina Medical, a subsidiary of Aamal Company, and Danish healthcare major Novo Nordisk have launched the weight loss prescription medicine Wegovy (Semaglutide 2.4mg) in Qatar, marking a medical ...

If you’d like a rough idea of what to expect, though, the Wegovy study we mentioned above found that those taking a 2.4 mg dose of semaglutide lost about. Beyond the one-year mark, semaglutide ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Wegovy (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above, is now ...

Wegovy® (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above1, is now ...